[
    [
        {
            "time": "",
            "original_text": "沃森生物：公司新冠mRNA疫苗的临床试验在正常推进中",
            "features": {
                "keywords": [
                    "沃森生物",
                    "新冠",
                    "mRNA疫苗",
                    "临床试验",
                    "正常推进"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "沃森生物：公司新冠mRNA疫苗的临床试验在正常推进中",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "沃森生物(300142.SZ)获得1项发明专利证书",
            "features": {
                "keywords": [
                    "沃森生物",
                    "发明专利",
                    "证书"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "沃森生物(300142.SZ)获得1项发明专利证书",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        }
    ]
]